The US National PKU Alliance invested in portfolio company Pluvia Biotech, developer of oral therapies for phenylketonuria.
Pluvia Biotech is a Norwegian biotech company focused on developing treatments for genetic disorders caused by protein misfolding, particularly targeting phenylketonuria (PKU)
Pluvia Biotech is a Norwegian biotech company focused on developing treatments for genetic disorders caused by protein misfolding, particularly targeting phenylketonuria (PKU). It aims to provide PKU patients with an oral treatment option.